James T Dalton
James T Dalton
Verified email at umich.edu
Title
Cited by
Cited by
Year
Chemistry and structural biology of androgen receptor
W Gao, CE Bohl, JT Dalton
Chemical reviews 105 (9), 3352-3370, 2005
4742005
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
JC Byrd, TS Lin, JT Dalton, D Wu, MA Phelps, B Fischer, M Moran, ...
Blood 109 (2), 399-404, 2007
4252007
Structural basis for antagonism and resistance of bicalutamide in prostate cancer
CE Bohl, W Gao, DD Miller, CE Bell, JT Dalton
Proceedings of the National Academy of Sciences 102 (17), 6201-6206, 2005
3842005
Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging
S Bhasin, OM Calof, TW Storer, ML Lee, NA Mazer, R Jasuja, VM Montori, ...
Nature clinical practice Endocrinology & metabolism 2 (3), 146-159, 2006
3032006
Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies
S Dodson, VE Baracos, A Jatoi, WJ Evans, D Cella, JT Dalton, MS Steiner
Annual review of medicine 62, 265-279, 2011
2732011
Discovery of nonsteroidal androgens
JT Dalton, A Mukherjee, Z Zhu, L Kirkovsky, DD Miller
Biochemical and biophysical research communications 244 (1), 1-4, 1998
2601998
The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double …
JT Dalton, KG Barnette, CE Bohl, ML Hancock, D Rodriguez, ST Dodson, ...
Journal of cachexia, sarcopenia and muscle 2 (3), 153, 2011
2572011
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial
AS Dobs, RV Boccia, CC Croot, NY Gabrail, JT Dalton, ML Hancock, ...
The lancet oncology 14 (4), 335-345, 2013
2442013
MOSFET gate electrodes having performance tuned work functions and methods of making same
JP Barnak, RS Chau, C Liang
US Patent 7,022,559, 2006
2162006
Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9* 3 allele.
RS Kidd, AB Straughn, MC Meyer, J Blaisdell, JA Goldstein, JT Dalton
Pharmacogenetics 9 (1), 71-80, 1999
2151999
Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs)
W Gao, JT Dalton
Drug discovery today 12 (5-6), 241-248, 2007
2112007
Pharmacodynamics of selective androgen receptor modulators
D Yin, W Gao, JD Kearbey, H Xu, K Chung, Y He, CA Marhefka, ...
Journal of Pharmacology and Experimental Therapeutics 304 (3), 1334-1340, 2003
1962003
Synthesis and antiproliferative activity of 2-aryl-4-oxo-thiazolidin-3-yl-amides for prostate cancer
V Gududuru, E Hurh, JT Dalton, DD Miller
Bioorganic & medicinal chemistry letters 14 (21), 5289-5293, 2004
1942004
Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit
ML Mohler, CE Bohl, A Jones, CC Coss, R Narayanan, Y He, DJ Hwang, ...
Journal of medicinal chemistry 52 (12), 3597-3617, 2009
1932009
Structural basis for accommodation of nonsteroidal ligands in the androgen receptor
CE Bohl, DD Miller, J Chen, CE Bell, JT Dalton
Journal of Biological Chemistry 280 (45), 37747-37754, 2005
1872005
Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats
W Gao, PJ Reiser, CC Coss, MA Phelps, JD Kearbey, DD Miller, ...
Endocrinology 146 (11), 4887-4897, 2005
1872005
Favorable effects of weak acids on negative-ion electrospray ionization mass spectrometry
Z Wu, W Gao, MA Phelps, D Wu, DD Miller, JT Dalton
Analytical chemistry 76 (3), 839-847, 2004
1842004
Favorable effects of weak acids on negative-ion electrospray ionization mass spectrometry
Z Wu, W Gao, MA Phelps, D Wu, DD Miller, JT Dalton
Analytical chemistry 76 (3), 839-847, 2004
1842004
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
MA Phelps, TS Lin, AJ Johnson, E Hurh, DM Rozewski, KL Farley, D Wu, ...
Blood, The Journal of the American Society of Hematology 113 (12), 2637-2645, 2009
1802009
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma
Q Liu, X Zhao, F Frissora, Y Ma, R Santhanam, D Jarjoura, A Lehman, ...
Blood, The Journal of the American Society of Hematology 111 (1), 275-284, 2008
1622008
The system can't perform the operation now. Try again later.
Articles 1–20